

Alexion presentations during the 2025 AANEM Annual Meeting and MGFA Scientific Session

Lead Author	Abstract Title	Presentation Details
Gwathmey, K.	Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis (PREVAIL): Topline results from a phase 3, randomized, double-blind, placebo-controlled study	MGFA Scientific Session Oral Presentation 29 October 2025 11:30 – 11:39 PST
Ragole, T.	Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with generalized myasthenia gravis in the United States (<i>Encore</i>)	MGFA Scientific Session Oral Presentation 118 29 October 2025 13:00 – 13:07 PST
Akpoji, U.	Characterization of antibiotic prophylaxis risk mitigation practices across Alexion complement 5 inhibitor phase III clinical trials	MGFA Scientific Session Oral Presentation 99 29 October 2025 13:32 – 13:39 PST
Pandya, S.	Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder: an updated analysis of US clinical practice	MGFA Scientific Session Oral Presentation 109 29 October 2025 13:40 – 13:47 PST
Gwathmey, K.	Usability of gefurulimab autoinjector (AI) and Prefilled Syringe (PFS) devices: A human factors (HF) validation study	MGFA Scientific Session Poster Presentation 34 29 October 2025 From 14:30 – 15:00 PST
McEneny, A.	Phase 1 study evaluating gefurulimab pharmacokinetics and safety following delivery via autoinjector or prefilled syringe in healthy adults	MGFA Scientific Session Poster Presentation 52 29 October 2025 From 14:30 – 15:00 PST
Saccà, F.	Assessing efficacy and safety of gefurulimab in generalized myasthenia gravis: baseline characteristics from PREVAIL (<i>Encore</i>)	MGFA Scientific Session Poster Presentation 74 29 October 2025 From 14:30 – 15:00 PST
Scheiner, C.	Outcomes for patients receiving ravulizumab or efgartigimod treatment within two years of generalized myasthenia gravis (gMG) diagnosis: A retrospective sub-analysis of US medical records	MGFA Scientific Session Poster Presentation 78 29 October 2025 From 14:30 – 15:00 PST

Lead Author	Abstract Title	Presentation Details
Yungher, B.	Assessing oral corticosteroid tapering in ravulizumab-treated adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: The phase 4, a global OCTAGON study design	MGFA Scientific Session Poster Presentation 92 29 October 2025 From 14:30 – 15:00 PST
Ragole, T.	Corticosteroid toxicity and related healthcare resource utilization in patients with myasthenia gravis in the USA	MGFA Scientific Session Poster Presentation 118 29 October 2025 From 14:30 – 15:00 PST
Snook, R.	Healthcare resource utilization in early initiators of ravulizumab versus efgartigimod for treatment of generalized myasthenia gravis in the USA	MGFA Scientific Session Poster Presentation 12 29 October 2025 From 14:30 – 15:00 PST
Bhattacharyya, S.	Predictors of myasthenia gravis hospitalizations in the PREDICT Study	MGFA Scientific Session Poster Presentation 10 29 October 2025 From 14:30 – 15:00 PST
Kutz, C.	Retrospective analysis of efgartigimod alfa-fcab or efgartigimod alfa and hyaluronidase-qvfc switches to ravulizumab in patients with Myasthenia Gravis (MG)	MGFA Scientific Session Poster Presentation 97 29 October 2025 From 14:30 – 15:00 PST
Kutz, C.	Retrospective analysis of intravenous immunoglobulin (IVIg) infusion switches to ravulizumab (Ultomiris) in patients with myasthenia gravis (MG)	MGFA Scientific Session Poster Presentation 98 29 October 2025 From 14:30 – 15:00 PST
Narayanswami, P.	Effectiveness and safety of ravulizumab in generalized myasthenia gravis: Updated Registry analyses (<i>Encore</i>)	AANEM Annual Meeting Poster Presentation 189 Session I: 30 October 2025 from 18:15 – 18:45 PST Session II: 31 October 2025 from 9:30 – 10:00 PST
Nowak, R.	Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalized myasthenia gravis global Registry (<i>Encore</i>)	AANEM Annual Meeting Poster Presentation 190 Session I: 30 October 2025 from 18:15 – 18:45 PST Session II: 31 October 2025 from 9:30 – 10:00 PST

Lead Author	Abstract Title	Presentation Details
Streicher, N.	Prediction of myasthenia gravis crisis events by a machine learning algorithm (adaptation)	AANEM Annual Meeting Poster Presentation 187 Session I: 30 October 2025 from 18:15 – 18:45 PST Session III: 31 October 2025 from 14:45 – 15:15 PST
Silvestri, N.	Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal Fc receptor inhibitors (<i>Encore</i>)	AANEM Annual Meeting Poster Presentation 188 Session I: 30 October 2025 from 18:15 – 18:45 PST Session III: 31 October 2025 from 14:45 – 15:15 PST